Learnings from the recent experience, remaining uncertainties and Gaps
Pauline Thémans1 , Nicolas Dauby2,3, Loïc Schrooyen2, Faustine Lebout2, Marc Delforge2, Rakan Nasreddinne2, Agnès Libois2, Marie-Christine Payen2, Déborah Konopnicki2, Francoise Wuillaume4, Cecile Lescrainier4, Veerle Verlinden4, Jean-Michel Dogné4,5, Jamila Hamdani4, and Flora T. Musuamba4,6
1. Namur Institute for Complex System (naXys) and Department of Mathematics, University of Namur, Namur, Belgium
2. Department of Infectious Diseases, Centre Hospitalier Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels
3. Environmental Health Research Centre, Public Health School, Université Libre de Bruxelles (ULB), Brussels, Belgium
4. Belgian Federal Agency for Medicines and Health Products, Brussels, Belgium
5 Namur Thrombosis and Hemostasis Center, Department of Pharmacy, University of Namur, Namur, Belgium
6. Faculty of Pharmaceutical sciences, University of Lubumbashi, Lubumbashi, DR Congo